Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aqneursa
Pharma
Shionogi acquires IntraBio to bolster rare disease business
Shionogi is scooping up IntraBio and its lead asset, Aqneursa, in a $2 billion deal just weeks after IntraBio's key FDA label expansion.
Donavyn Coffey
Oct 5, 2026 11:33am
IntraBio's Aqneursa scores FDA approval for rare ataxia
Sep 21, 2026 11:10am
IntraBio's Aqneursa tees up 2nd rare disease nod with ph. 3 win
Jan 21, 2026 11:48am
Zevra pegs Miplyffa as 'cornerstone' of Niemann-Pick treatment
Oct 4, 2024 6:45am
IntraBio hits the ground running with new rare disease launch
Sep 30, 2024 3:25pm
IntraBio snags FDA nod in rare disease just days after Zevra
Sep 25, 2024 9:50am
